Carlsmed
Carlsmed's revenue rose 85.9% to $50 million in fiscal 2025. Its operating margin was −60.5%, up from −88.8% a year earlier. Free cash flow was −$30 million. The diluted share count rose 249.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
What Carlsmed does
Carlsmed is a medical technology company that sells personalized implants and planning software for spine fusion surgery. Its aprevo platform uses AI-based software and a patient's imaging to design a surgical plan and interbody implants (spacers placed between vertebrae) shaped to fit that patient's spine. Each kit includes the custom implants and single-use surgical instruments. It has FDA clearance for lumbar and cervical uses.
It sells to hospitals and ambulatory surgical centers through its own sales team and independent agents, mainly in the U.S. All its revenue comes from aprevo implants. For 2025 it recognized revenue of $50.5 million. As of December 31, 2025, 253 surgeons had completed one or more procedures with the platform.
Carlsmed uses a small number of contract manufacturers to make, sterilize and ship the implants. It competes with companies that sell traditional stock implants.
Its biggest risks, as it describes them
- Depending entirely on sales of aprevo implants and on surgeons adopting the platform.
- A history of net losses, with more losses expected.
- Relying on a limited number of contract manufacturers for its implants.
- Needing to commercialize the platform for cervical spine surgery to grow.
- Product liability claims and recalls.
Income statement
Carlsmed lost money in fiscal 2025: a net loss of $30 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | 40 | 110 |
| Debt incl. finance leases | 15 | 15 |
| Net debt (negative means net cash) | −25 | −94 |
| Net debt to EBITDA | — | — |
| Debt to equity | — | 0.2x |
| Interest coverage | −18.3x | −21.4x |
| Current ratio | 5.6x | 8.9x |
| Quick ratio | 5.5x | 8.7x |
Cash flow
Projections
Project Carlsmed's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Carlsmed says to expect
- Full year 2026: revenue
Revenue for the full year 2026 is expected to be in the range of $78 million to $80 million, representing growth of over 56% at the midpoint.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Carlsmed shares on the open market, and 1 insider sold $2.6 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | Michael CordonnierCEO, President, Director | Sold | 197,855 | $13.29 | $2.6 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY25 |
|---|---|
| Piotroski F-score | — |
| Rule of 40 | 27.3% |
| Altman Z'' | 4.88 |
| Accruals ratio | −0.7% |
The nine F-score tests
| Test | FY25 |
|---|---|
| Net income is positive | Fail |
| Cash from operations is positive | Fail |
| Return on assets rose | — |
| Cash from operations exceeds net income | Pass |
| Debt fell relative to assets | — |
| Current ratio rose | Pass |
| Share count didn't rise | Fail |
| Gross margin rose | Pass |
| Revenue rose relative to assets | — |
| F-score | — |
Compare
Put Carlsmed side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Carlsmed | FY25 | 85.9% | −60.5% | −58.6% | — | — | — | |
| IRIDEX | FY25 | 8.2% | −4.9% | −4.3% | — | — | — | Compare |
| Apyx Medical | FY25 | 9.9% | −12.2% | −17.2% | −25.0% | — | 4 | Compare |
| Shoulder Innovations | FY25 | 49.6% | −55.6% | −76.1% | — | — | — | Compare |
| TriSalus Life Sciences | FY25 | 53.4% | −59.7% | −41.9% | — | — | 3 | Compare |
2 years of figures
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Revenue | 27 | 50 |
| Revenue growth | — | 85.9% |
| Gross profit | 20 | 38 |
| Research and development | 14 | 17 |
| Operating income | −24 | −31 |
| Net income | −24 | −30 |
| Diluted EPS (US$) | −6.11 | −2.12 |
| Diluted shares (millions) | 4 | 14 |
| Cash flow | ||
| Cash from operations | −26 | −29 |
| Capital expenditure | 0 | 1 |
| Free cash flow | −26 | −30 |
| Dividends paid | 0 | 0 |
| Share buybacks | 0 | 0 |
| Acquisitions | 0 | 0 |
| Stock-based compensation | 0 | 2 |
| Balance sheet at fiscal year end | ||
| Cash and short-term investments | 40 | 110 |
| Debt incl. finance leases | 15 | 15 |
| Total assets | 52 | 130 |
| Total liabilities | 26 | 31 |
| Shareholders' equity | −71 | 99 |
| Margins and ratios | ||
| Gross margin | 73.8% | 75.3% |
| Operating margin | −88.8% | −60.5% |
| Net margin | −89.3% | −58.7% |
| Free cash flow margin | −94.4% | −58.6% |
| Rule of 40 (growth + FCF margin) | — | 27.3% |
| Return on capital | — | — |
| Return on equity | — | −209.9% |
| Return on assets | — | −32.6% |
| Net debt to EBITDA | — | — |